Cite
HARVARD Citation
Heibl, S. et al. (2020). A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1. Hematological oncology. 38 (5), pp. 792-798. [Online].